Immix Biopharma, Inc. (IMMX) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on chimeric antigen receptor (CAR-T) cell therapy for light chain (AL) Amyloidosis. The Company's lead candidate, NXC-201, is currently in a Phase 1b/2 clinical trial (NEXICART-2). As of the reporting date, the Company holds Breakthrough Therapy Designation from the FDA for NXC-201 in relapsed/refractory AL amyloidosis.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(21,643,689) | $(11,165,091) |
| Operating Expenses | $23,260,198 | $11,400,630 |
| Research & Development (R&D) | $11,313,649 | $5,947,532 |
| General & Administrative (G&A) | $11,946,549 | $5,453,098 |
| Interest Income | $1,630,831 | $254,275 |
| Cash & Cash Equivalents (End of Period) | $225,491,985 | $11,637,945 |
| Total Investments (Short & Long Term) | $8,667,310 | $0 |
| Total Liabilities | $10,192,343 | $11,044,171 |
| Working Capital | $224,488,366 | $91,127,209 |
Material Changes vs. Prior Period
- Capital Raise: The Company significantly strengthened its balance sheet through equity financing. In May 2026, it completed an underwritten public offering raising approximately $140.7 million (net). Additionally, it raised $13.9 million via its At-The-Market (ATM) facility during the six-month period.
- Expense Growth: Total operating expenses increased by approximately 104% year-over-year. R&D expenses rose due to the expansion of the NEXICART-2 clinical trial and license fees. G&A expenses increased due to higher compensation, stock-based compensation, and professional fees related to capital raising activities.
- Liquidity: Cash and cash equivalents increased from approximately $93.9 million at year-end 2025 to $225.5 million at June 30, 2026, driven primarily by financing activities.
- Grant Income: The Company received approximately $2.0 million in reimbursements from the California Institute for Regenerative Medicine (CIRM) grant, recorded as an offset to R&D expenses.
Guidance, Outlook, and Risks
- Clinical Progress: Interim data from the NEXICART-2 trial showed a 95% Complete Response (CR) rate (19 out of 20 patients) with no relapses observed to date. The Company plans to initiate a multi-center, randomized Phase 3 trial in newly diagnosed AL Amyloidosis patients.
- Liquidity Outlook: Management believes current cash, cash equivalents, and short-term investments (~$232 million) are sufficient to fund operations for at least the next 12 months. However, additional capital will be required beyond that period.
- Risk Factors:
- Interim Data Risk: Final clinical trial results may differ materially from interim data presented.
- Regulatory Risk: No assurance that NXC-201 will receive FDA approval or that the Breakthrough Therapy designation will lead to accelerated approval.
- Financing Risk: Continued dependence on equity financing may result in significant dilution to existing shareholders.
- Going Concern: While currently funded, the Company has a history of losses and an accumulated deficit of $126.1 million.
Investor Verification Checklist
- Cash Runway: Verify the burn rate against the $225.5 million cash balance to confirm the 12-month liquidity assertion.
- Clinical Trial Status: Confirm the timeline and enrollment status for the planned Phase 3 trial in newly diagnosed patients.
- Dilution Impact: Review the total share count (71.5 million outstanding) and the impact of outstanding options (6.9 million) and warrants (5.3 million) on future dilution.
- Grant Milestones: Monitor the achievement of CIRM grant milestones to ensure the remaining $1.3 million of awarded funds is disbursed.
- License Obligations: Review the payment schedule for the Hadasit/BIRAD license agreement, which includes quarterly payments totaling ~$13 million through September 2026.